Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis

被引:58
作者
Atkins, GJ
Bouralexis, S
Evdokiou, A
Hay, S
Labrinidis, A
Zannettino, ACW
Haynes, DR
Findlay, DM
机构
[1] Univ Adelaide, Dept Orthopaed & Trauma, Adelaide, SA 5000, Australia
[2] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[3] Univ Adelaide, Inst Med & Vet Sci, Div Haematol, Adelaide, SA 5000, Australia
[4] Univ Adelaide, Dept Pathol, Adelaide, SA 5000, Australia
基金
英国医学研究理事会;
关键词
human osteoblasts; Apo2L/TRAIL; receptors; apoptosis; caspase; chemotherapy;
D O I
10.1016/S8756-3282(02)00858-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Apo2 ligand (Apo2L/TRAIL) is a member of the tumor necrosis factor (TNF) cytokine family. Apo2L/TRAIL can selectively induce programmed cell death in transformed cells, although its wide tissue distribution suggests potential physiological roles. We have investigated the expression, in human osteoblast-like cells (NHBC), of Apo2L/TRAIL and the known Apo2L/TRAIL death receptors, DR4 and DR5, and the Apo2L/TRAIL decoy receptors, DcR-1, DcR-2, and osteoprotegerin (OPG). NHBC expressed abundant mRNA corresponding to each of these molecular species. Immunofluorescence staining demonstrated that Apo2L/TRAIL protein was abundant within the cytoplasm of NHBC and OPG was strongly expressed at the cell surface. DR5 and DcR-2 were present in the cell membrane and cytoplasm and DcR-1 was confined to the nucleus. DR4 staining was weak. Neither Apo2L/TRAIL alone, nor in combination with chemotherapeutic agents of clinical relevance to treatment of osteogenic sarcoma, induced cell death in NRBC, as assessed morphologically and by activation of caspase-3. In contrast, the human osteogenic sarcoma cell lines, BTK-143 and G-292, were sensitive to exogenous Apo2L/TRAIL alone, and to the combined effect of Apo2L/TRAIL/cisplatin and Apo2L/TRAIL/doxorubicin treatments, respectively. In NHBC, we observed strong associations between the levels of mRNA corresponding to the pro-apoptotic molecules, Apo2L/TRAIL, DR4, and DR5, and those corresponding to prosurvival molecules, DcR-1, DcR-2, OPG, and FLIP, suggesting that the balance between pro-survival and pro-apoptotic molecules is a mechanism by which NHBC can resist Apo2L/TRAIL-mediated apoptosis. In contrast, osteogenic sarcoma cells had low or absent levels of DcR-1 and DcR-2. These results provide a foundation to explore the role of Apo2L/TRAIL in osteoblast physiology. In addition, they predict that therapeutic use of recombinant Apo2L/TRAIL, in combination with chemotherapeutic agents to treat skeletal malignancies, would have limited toxic effects on normal osteoblastic cells.
引用
收藏
页码:448 / 456
页数:9
相关论文
共 44 条
  • [1] Safety and antitumor activity of recombinant soluble Apo2 ligand
    Ashkenazi, A
    Pai, RC
    Fong, S
    Leung, S
    Lawrence, DA
    Masters, SA
    Blackie, C
    Chang, L
    McMurtrey, AE
    Hebert, A
    DeForge, L
    Koumenis, IL
    Lewis, D
    Harris, L
    Bussiere, J
    Koeppen, H
    Shahrokh, Z
    Schwall, RH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) : 155 - 162
  • [2] Death receptors: Signaling and modulation
    Ashkenazi, A
    Dixit, VM
    [J]. SCIENCE, 1998, 281 (5381) : 1305 - 1308
  • [3] Expression of osteoclast differentiation signals by stromal elements of giant cell tumors
    Atkins, GJ
    Haynes, DR
    Graves, SE
    Evdokiou, A
    Hay, S
    Bouralexis, S
    Findlay, DM
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (04) : 640 - 649
  • [4] Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone
    Atkins, GJ
    Bouralexis, S
    Haynes, DR
    Graves, SE
    Geary, SM
    Evdokiou, A
    Zannettino, ACW
    Hay, S
    Findlay, DM
    [J]. BONE, 2001, 28 (04) : 370 - 377
  • [5] Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway
    Chaudhary, PM
    Eby, M
    Jasmin, A
    Bookwalter, A
    Murray, J
    Hood, L
    [J]. IMMUNITY, 1997, 7 (06) : 821 - 830
  • [6] The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
    Degli-Esposti, MA
    Dougall, WC
    Smolak, PJ
    Waugh, JY
    Smith, CA
    Goodwin, RG
    [J]. IMMUNITY, 1997, 7 (06) : 813 - 820
  • [7] Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
    DegliEsposti, MA
    Smolak, PJ
    Walczak, H
    Waugh, J
    Huang, CP
    DuBose, RF
    Goodwin, RG
    Smith, CA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) : 1165 - 1170
  • [8] Cyclooxygenase-2: a novel target for cancer chemotherapy?
    Dempke, W
    Rie, C
    Grothey, A
    Schmoll, HJ
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2001, 127 (07) : 411 - 417
  • [9] Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
    Emery, JG
    McDonnell, P
    Burke, MB
    Deen, KC
    Lyn, S
    Silverman, C
    Dul, E
    Appelbaum, ER
    Eichman, C
    DiPrinzio, R
    Dodds, RA
    James, IE
    Rosenberg, M
    Lee, JC
    Young, PR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (23) : 14363 - 14367
  • [10] Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRIAL-induced apoptosis
    Evdokiou, A
    Bouralexis, S
    Atkins, GJ
    Chai, F
    Hay, S
    Clayer, M
    Findlay, DM
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (04) : 491 - 504